European Association for the Study of Diabetes (EASD): Annual Meeting 2025 Highlights

The European Association for the Study of Diabetes (EASD) is a leading academic, non-profit organization dedicated to advancing research, education, and care in the field of diabetes mellitus. Founded in 1965 and headquartered in Düsseldorf, Germany, EASD brings together scientists, clinicians, nurses, allied health professionals, and students from around the world who are interested in diabetes research and its clinical application.

EASD 2025 took place in Vienna, Austria, between 15-19 September 2025.
The infectious diseases team attended industry-sponsored and scientific sessions where key therapies were featured, the contents of which were analyzed to create this IDWeek 2025 Highlights report.

Report Scope

Indications, companies, and therapies discussed:

GLP-1RAs

• Novo Nordisk - Semaglutide & Cagrilintide

Cardiovascular Disease

• Regeneron Pharmaceuticals & Sanofi - Alirocumab

Resistant Hypertension

• AstraZeneca - Baxdrostat

Type 1 & Type 2 Diabetes

• SAB Biotherapeutics - SAB-142
• Vertex Pharmaceuticals - VX-880

And more!

Reasons to Buy

This powerpoint-based deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as Type 1 Diabetes, Type 2 Diabetes, Obesity, Heart Failure, Dyslipidemia, and more.

Inside the report you’ll find:

• Emerging trends in cardiovascular and metabolic indications
• Insights into the disease areas that took precedence at the conference
• Key takeaways from headline sessions and late-breaking data
• Clinical and commercial implications of notable presentations